ProQR Therapeutics (PRQR) Common Equity (2021 - 2024)
Historic Common Equity for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $94.6 million.
- ProQR Therapeutics' Common Equity rose 11250.42% to $94.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $94.6 million, marking a year-over-year increase of 11250.42%. This contributed to the annual value of $95.9 million for FY2024, which is 11408.75% up from last year.
- As of Q4 2024, ProQR Therapeutics' Common Equity stood at $94.6 million, which was up 11250.42% from $44.5 million recorded in Q4 2023.
- Over the past 5 years, ProQR Therapeutics' Common Equity peaked at $151.7 million during Q3 2021, and registered a low of $59993.4 during Q1 2021.
- In the last 4 years, ProQR Therapeutics' Common Equity had a median value of $68.0 million in 2022 and averaged $82.6 million.
- Data for ProQR Therapeutics' Common Equity shows a peak YoY increase of 18852786.02% (in 2022) and a maximum YoY decrease of 5683.98% (in 2022) over the last 5 years.
- Over the past 4 years, ProQR Therapeutics' Common Equity (Quarter) stood at $130.5 million in 2021, then crashed by 47.88% to $68.0 million in 2022, then crashed by 34.54% to $44.5 million in 2023, then soared by 112.5% to $94.6 million in 2024.
- Its Common Equity was $94.6 million in Q4 2024, compared to $44.5 million in Q4 2023 and $50.4 million in Q3 2023.